Incyte bags more Jakafi studies in solid tumors, but maintains hope for combo success

Incyte ($INCY) pulled the plug on several Jakafi studies as the blood cancer therapy proved less effective in solid tumors when used solo. The company still sees potential in the field with Jakafi cocktails, including combos that pair the med with immuno-oncology meds. Jakafi is marketed outside the U.S. by Novartis ($NVS), which brought in $410 million from the drug last year; Incyte's U.S. sales amounted to $601 million. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.